Jiangxi Fushine Pharmaceutical Co Ltd (300497) - Net Assets
Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) has net assets worth CN¥2.27 Billion CNY (≈ $332.03 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.48 Billion ≈ $655.46 Million USD) and total liabilities (CN¥2.21 Billion ≈ $323.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Jiangxi Fushine Pharmaceutical Co Ltd's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.27 Billion |
| % of Total Assets | 50.66% |
| Annual Growth Rate | 23.05% |
| 5-Year Change | -24.43% |
| 10-Year Change | 180.57% |
| Growth Volatility | 36.53 |
Jiangxi Fushine Pharmaceutical Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Jiangxi Fushine Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual net assets of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025. For live valuation and market cap data, see market value of Jiangxi Fushine Pharmaceutical Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.20 Billion ≈ $321.96 Million |
+1.07% |
| 2024-12-31 | CN¥2.18 Billion ≈ $318.55 Million |
-11.89% |
| 2023-12-31 | CN¥2.47 Billion ≈ $361.55 Million |
-8.14% |
| 2022-12-31 | CN¥2.69 Billion ≈ $393.58 Million |
-7.61% |
| 2021-12-31 | CN¥2.91 Billion ≈ $426.02 Million |
-4.48% |
| 2020-12-31 | CN¥3.05 Billion ≈ $445.98 Million |
+99.52% |
| 2019-12-31 | CN¥1.53 Billion ≈ $223.52 Million |
+33.21% |
| 2018-12-31 | CN¥1.15 Billion ≈ $167.80 Million |
+18.62% |
| 2017-12-31 | CN¥966.71 Million ≈ $141.46 Million |
+23.28% |
| 2016-12-31 | CN¥784.17 Million ≈ $114.75 Million |
+31.53% |
| 2015-12-31 | CN¥596.21 Million ≈ $87.24 Million |
+110.48% |
| 2014-12-31 | CN¥283.26 Million ≈ $41.45 Million |
+23.29% |
| 2013-12-31 | CN¥229.76 Million ≈ $33.62 Million |
+24.46% |
| 2012-12-31 | CN¥184.60 Million ≈ $27.01 Million |
+53.17% |
| 2011-12-31 | CN¥120.52 Million ≈ $17.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangxi Fushine Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 117.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥209.49 Million | 9.59% |
| Other Components | CN¥1.97 Billion | 90.41% |
| Total Equity | CN¥2.18 Billion | 100.00% |
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangxi Fushine Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sino Prima Gas Technology Co Ltd
SHE:300483
|
$1.25 Billion |
|
Fsilon Furnishing and Construction Materials Corp
SHG:605318
|
$1.25 Billion |
|
Ruyizhou Inc
NYSE:RYZ
|
$1.25 Billion |
|
Ingenia Communities Group
AU:INA
|
$1.25 Billion |
|
Shunsin Technology Holdings Ltd
TW:6451
|
$1.25 Billion |
|
Jamieson Wellness Inc
TO:JWEL
|
$1.25 Billion |
|
Shanghai Electric Group Company Limited
F:USR
|
$1.25 Billion |
|
Titagarh Rail Systems Limited
NSE:TITAGARH
|
$1.25 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangxi Fushine Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,180,472,645 to 2,183,803,867, a change of 3,331,222 (0.2%).
- Net loss of 53,067,700 reduced equity.
- Dividend payments of 54,765,483 reduced retained earnings.
- Other comprehensive income decreased equity by 159,707,751.
- Other factors increased equity by 270,872,156.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-53.07 Million | -2.43% |
| Dividends Paid | CN¥54.77 Million | -2.51% |
| Other Comprehensive Income | CN¥-159.71 Million | -7.31% |
| Other Changes | CN¥270.87 Million | +12.4% |
| Total Change | CN¥- | 0.15% |
Book Value vs Market Value Analysis
This analysis compares Jiangxi Fushine Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 39.05x to 3.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.41 | CN¥15.90 | x |
| 2012-12-31 | CN¥0.62 | CN¥15.90 | x |
| 2013-12-31 | CN¥0.73 | CN¥15.90 | x |
| 2014-12-31 | CN¥0.91 | CN¥15.90 | x |
| 2015-12-31 | CN¥1.92 | CN¥15.90 | x |
| 2016-12-31 | CN¥1.79 | CN¥15.90 | x |
| 2017-12-31 | CN¥2.23 | CN¥15.90 | x |
| 2018-12-31 | CN¥2.58 | CN¥15.90 | x |
| 2019-12-31 | CN¥3.26 | CN¥15.90 | x |
| 2020-12-31 | CN¥6.50 | CN¥15.90 | x |
| 2021-12-31 | CN¥5.31 | CN¥15.90 | x |
| 2022-12-31 | CN¥4.93 | CN¥15.90 | x |
| 2023-12-31 | CN¥4.58 | CN¥15.90 | x |
| 2024-12-31 | CN¥4.09 | CN¥15.90 | x |
| 2025-12-31 | CN¥4.12 | CN¥15.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangxi Fushine Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.48%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 2.02x
- Recent ROE (-2.43%) is below the historical average (11.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 29.74% | 12.30% | 0.83x | 2.93x | CN¥23.79 Million |
| 2012 | 21.71% | 11.12% | 0.76x | 2.58x | CN¥21.62 Million |
| 2013 | 19.62% | 10.18% | 0.82x | 2.36x | CN¥22.10 Million |
| 2014 | 18.87% | 10.46% | 0.81x | 2.23x | CN¥25.11 Million |
| 2015 | 15.70% | 16.15% | 0.57x | 1.69x | CN¥33.98 Million |
| 2016 | 23.00% | 22.77% | 0.55x | 1.85x | CN¥98.31 Million |
| 2017 | 18.95% | 18.53% | 0.54x | 1.91x | CN¥83.86 Million |
| 2018 | 17.45% | 16.74% | 0.53x | 1.97x | CN¥83.10 Million |
| 2019 | 20.53% | 22.59% | 0.52x | 1.74x | CN¥156.84 Million |
| 2020 | 10.62% | 21.39% | 0.37x | 1.35x | CN¥18.57 Million |
| 2021 | 1.70% | 3.42% | 0.31x | 1.62x | CN¥-239.19 Million |
| 2022 | -5.28% | -8.59% | 0.33x | 1.89x | CN¥-409.60 Million |
| 2023 | -8.08% | -12.47% | 0.33x | 1.94x | CN¥-449.28 Million |
| 2024 | -12.48% | -23.10% | 0.26x | 2.08x | CN¥-490.15 Million |
| 2025 | -2.43% | -4.48% | 0.27x | 2.02x | CN¥-271.45 Million |
Industry Comparison
This section compares Jiangxi Fushine Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,138,003,765
- Average return on equity (ROE) among peers: 4.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangxi Fushine Pharmaceutical Co Ltd (300497) | CN¥2.27 Billion | 29.74% | 0.97x | $1.25 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $122.63 Million | -3.31% | 0.75x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $287.68 Million | 11.32% | 2.71x | $1.48 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $130.38 Million | -22.94% | 1.12x | $376.20 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $721.59 Million | 0.83% | 0.13x | $555.92 Million |
| Chengzhi Shareholding Co Ltd (000990) | $839.58 Million | 6.67% | 0.90x | $1.14 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.66 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $11.49 Billion | 5.29% | 0.03x | $5.10 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.53 Billion | 3.25% | 0.38x | $446.07 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.75 Billion | 16.55% | 0.19x | $1.76 Billion |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride… Read more